|
Terumo has received the device for evaluation; however, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11. h3: 81 - evaluation is in progress, but not yet concluded.
|
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on may 06, 2024.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added exp date).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (updated device evaluated by manufacturer).H4 (device manufacture date).H6 (identification of evaluation codes 10, 3331, 213, 67).The returned sample was inspected upon receipt to show no visual anomalies with the device.After rinsing the sample, it was tested for the pressure drop with bovine blood.The maximum blood flow rate of 5l/min was able to be achieved.Saline solution was flowed through the blood channel, no blood clots were noted.As the event could not be replicated in laboratory conditions, a definitive root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|